Episode Details

Shadd Dales and Anthony Varrell discuss Judge John Mulrooney’s decision to cancel next weeks tALJ hearing for the rescheduling of cannabis and what this means for the cannabis industry. Joining us as well is Aras Azadian, CEO of Avicanna, who will share his insights on the delay and the potential rescheduling of cannabis. Azadian will explain the key initiatives cannabis medical research companies must prepare for if and when rescheduling occurs. As research focusing on medical cannabis gains traction, we’re diving deeper into Avicanna Inc. (TSX: AVCN), a leader in cannabis medical research. We’ll ask Azadian his thoughts on the rescheduling delay, how Avicanna has positioned its pipeline compared to other companies, and the platform MyMedi.ca, designed to enhance the patient journey. 0:00:10 - DEA Rescheduling Delay Impact 0:03:09 - Medical Research for Rescheduling 0:04:40 - Avicanna's Evidence-Based Approach 0:07:26 - Avicanna's MyMedi & Insurance Coverages 0:10:00 - Challenges in Cannabis Insurance 0:13:59 - Canada's Cannabis Leadership and Avicanna's Global Expansion 0:20:07 - Vertical Integration Strategy 0:24:55 - Importance of Partnerships 0:30:00 - US Legalization Impact 0:34:36 - Brazil's Cannabis Market Opportunity #dea #aljhearing #cannabis #cannabisindustry #medicalcannabis #cannabisresearch Want to see more from Trade to Black? https://youtube.com/live/jfK9DUQpX3A   • Boris Jordan Talks 2025 Cannabis Tren...     • Takeaways From Tilray's Q2 Earnings R...   Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!

Listen Now